CRISPR Therapeutics' stock is down 19% since December, with a slow Casgevy launch and significant R&D investments, yet strong cash reserves provide a safety net. Q4 earnings show no revenue from ...
In late 2023, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) for sickle cell disease (SCD), marking the world ...
The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...
Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access ...
Like Queen Elizabeth, she loves horses and a great tiara moment. Meghan Markle's refreshed lifestyle brand has a logo with a meaningful symbol. On Feb. 18, the Duchess of Sussex announced that she ...
The biotech's Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed with Vertex Pharmaceuticals, is now approved in the U.S ...
While Casgevy is making progress based on 2024 revenue reported by Vertex (VRTX), it appears five patients have been treated since launch, the analyst tells investors in a research note.
With its flagship product Casgevy gaining traction and a diverse pipeline spanning multiple therapeutic areas, the company faces both significant opportunities and challenges in the rapidly evolving ...
With its flagship product Casgevy gaining traction and a diverse pipeline spanning multiple therapeutic areas, the company faces both significant opportunities and challenges in the rapidly ...
Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, is the first licensed therapy to utilise CRISPR/Cas9 gene-editing technology, whose inventors were awarded the 2020 Nobel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results